Refractory Diffuse large B-cell lymphoma NOS
Also known as: Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Drug | Drug Name | Drug Description |
---|---|---|
DB16371 | Glofitamab | A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. |
DB16222 | Loncastuximab tesirine | An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas. |
DB12240 | Polatuzumab vedotin | A CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma. |
DB11942 | Selinexor | Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated... |
DB15044 | Tafasitamab | A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB13915 | Axicabtagene ciloleucel | 1 | Recruiting | 1 |
DB02379 | Beta-D-Glucose | 1 | Withdrawn | 1 |
DB00262 | Carmustine | 1 | Withdrawn | 1 |
DB00531 | Cyclophosphamide | 1 | Recruiting | 1 |
DB00531 | Cyclophosphamide | 1 | Terminated | 2 |
DB00987 | Cytarabine | 1 | Withdrawn | 1 |
DB16395 | Efineptakin alfa | 1 | Recruiting | 1 |
DB00773 | Etoposide | 1 | Withdrawn | 1 |
DB01073 | Fludarabine | 1 | Recruiting | 1 |
DB01073 | Fludarabine | 1 | Terminated | 2 |
DB16582 | Lisocabtagene maraleucel | 1 | Recruiting | 2 |
DB16222 | Loncastuximab tesirine | 1 | Withdrawn | 1 |
DB00888 | Mechlorethamine | 1 | Withdrawn | 1 |
DB13881 | Tisagenlecleucel | 1 | Recruiting | 1 |
DB02379 | Beta-D-Glucose | 2 | Recruiting | 1 |
DB00958 | Carboplatin | 2 | Recruiting | 1 |
DB00531 | Cyclophosphamide | 2 | Recruiting | 1 |
DB00773 | Etoposide | 2 | Recruiting | 1 |
DB01181 | Ifosfamide | 2 | Recruiting | 1 |
DB00480 | Lenalidomide | 2 | Recruiting | 1 |
DB18441 | Maplirpacept | 2 | Recruiting | 1 |
DB17116 | Ontorpacept | 2 | Recruiting | 1 |
DB09037 | Pembrolizumab | 2 | Recruiting | 1 |
DB15044 | Tafasitamab | 2 | Recruiting | 1 |
DB15035 | Zanubrutinib | 2 | Recruiting | 1 |